HIF‐1β might also represent a potential target for treatment of MM carrying adverse CAs (eg, 1q21 gain) or acquired drug resistance, as well as for overcoming microenvironment‐mediated drug resistance. The gene discussed is ARNT; the disease is Miyoshi myopathy.